S&P 500   3,852.29 (+0.01%)
DOW   31,183.95 (-0.01%)
QQQ   325.61 (+0.57%)
AAPL   136.15 (+3.12%)
MSFT   226.02 (+0.75%)
FB   272.09 (+1.72%)
GOOGL   1,901.25 (+1.13%)
AMZN   3,318.43 (+1.69%)
TSLA   847.42 (-0.36%)
NVDA   543.86 (+1.73%)
BABA   259.08 (-2.41%)
CGC   33.64 (+0.03%)
GE   11.12 (-2.37%)
MU   83.44 (-0.07%)
AMD   90.11 (+1.53%)
NIO   57.84 (+0.23%)
T   28.87 (-0.31%)
F   11.72 (+7.92%)
ACB   11.11 (-3.73%)
BA   207.21 (-2.01%)
DIS   171.77 (-1.08%)
NFLX   571.94 (-2.46%)
GILD   66.81 (-1.74%)
S&P 500   3,852.29 (+0.01%)
DOW   31,183.95 (-0.01%)
QQQ   325.61 (+0.57%)
AAPL   136.15 (+3.12%)
MSFT   226.02 (+0.75%)
FB   272.09 (+1.72%)
GOOGL   1,901.25 (+1.13%)
AMZN   3,318.43 (+1.69%)
TSLA   847.42 (-0.36%)
NVDA   543.86 (+1.73%)
BABA   259.08 (-2.41%)
CGC   33.64 (+0.03%)
GE   11.12 (-2.37%)
MU   83.44 (-0.07%)
AMD   90.11 (+1.53%)
NIO   57.84 (+0.23%)
T   28.87 (-0.31%)
F   11.72 (+7.92%)
ACB   11.11 (-3.73%)
BA   207.21 (-2.01%)
DIS   171.77 (-1.08%)
NFLX   571.94 (-2.46%)
GILD   66.81 (-1.74%)
S&P 500   3,852.29 (+0.01%)
DOW   31,183.95 (-0.01%)
QQQ   325.61 (+0.57%)
AAPL   136.15 (+3.12%)
MSFT   226.02 (+0.75%)
FB   272.09 (+1.72%)
GOOGL   1,901.25 (+1.13%)
AMZN   3,318.43 (+1.69%)
TSLA   847.42 (-0.36%)
NVDA   543.86 (+1.73%)
BABA   259.08 (-2.41%)
CGC   33.64 (+0.03%)
GE   11.12 (-2.37%)
MU   83.44 (-0.07%)
AMD   90.11 (+1.53%)
NIO   57.84 (+0.23%)
T   28.87 (-0.31%)
F   11.72 (+7.92%)
ACB   11.11 (-3.73%)
BA   207.21 (-2.01%)
DIS   171.77 (-1.08%)
NFLX   571.94 (-2.46%)
GILD   66.81 (-1.74%)
S&P 500   3,852.29 (+0.01%)
DOW   31,183.95 (-0.01%)
QQQ   325.61 (+0.57%)
AAPL   136.15 (+3.12%)
MSFT   226.02 (+0.75%)
FB   272.09 (+1.72%)
GOOGL   1,901.25 (+1.13%)
AMZN   3,318.43 (+1.69%)
TSLA   847.42 (-0.36%)
NVDA   543.86 (+1.73%)
BABA   259.08 (-2.41%)
CGC   33.64 (+0.03%)
GE   11.12 (-2.37%)
MU   83.44 (-0.07%)
AMD   90.11 (+1.53%)
NIO   57.84 (+0.23%)
T   28.87 (-0.31%)
F   11.72 (+7.92%)
ACB   11.11 (-3.73%)
BA   207.21 (-2.01%)
DIS   171.77 (-1.08%)
NFLX   571.94 (-2.46%)
GILD   66.81 (-1.74%)
Log in
ASX:NXS

Next Science Limited (NXS.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$1.62
MA: A$1.62
A$1.62
52-Week Range N/A
Volume86,564 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Next Science Limited, a medical technology company, researches, develops, and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria in the United States and Australia. The company develops its products using its Xbio Technology platform. It offers SurgX, an innovative surgical gel designed to reduce superficial surgical site infections and protect wound tissue to facilitate natural healing; and Bactisure, a surgical lavage that is used to remove debris, including microorganisms from wounds. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. In addition, it is developing acne cream and cleanser. Next Science Limited was founded in 2012 and is headquartered in Sydney, Australia.

MarketRank

Overall MarketRank

0.83 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 8607 5124
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.77 million
Book ValueA$0.07 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive NXS News and Ratings via Email

Sign-up to receive the latest news and ratings for NXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Next Science Limited (NXS.AX) (ASX:NXS) Frequently Asked Questions

What stocks does MarketBeat like better than Next Science Limited (NXS.AX)?

Wall Street analysts have given Next Science Limited (NXS.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Next Science Limited (NXS.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Next Science Limited (NXS.AX)'s key competitors?

What other stocks do shareholders of Next Science Limited (NXS.AX) own?

Who are Next Science Limited (NXS.AX)'s key executives?

Next Science Limited (NXS.AX)'s management team includes the following people:
  • Ms. Judith Mitchell M.B.A., MD, CEO & Director
  • Dr. Matthew Myntti, Founder & CTO
  • Ms. Jacqueline Butler CA (ICAEW), Chief Financial Officer
  • Mr. Jon Swanson, Chief Operating Officer
  • Mr. Dustin Haines, Chief Commercial Officer
  • Ms. Gillian Maria Nairn, Company Sec.

What is Next Science Limited (NXS.AX)'s stock symbol?

Next Science Limited (NXS.AX) trades on the ASX under the ticker symbol "NXS."

How big of a company is Next Science Limited (NXS.AX)?

Next Science Limited (NXS.AX) has a market capitalization of $0.00 and generates $2.77 million in revenue each year.

What is Next Science Limited (NXS.AX)'s official website?

The official website for Next Science Limited (NXS.AX) is www.nextscience.com.

How can I contact Next Science Limited (NXS.AX)?

The company can be reached via phone at 61 2 8607 5124.

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.